Lucid Diagnostics to Participate in Upcoming Investor Conferences
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has announced its participation in two upcoming investor conferences in August 2025.
The company will attend the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference for one-on-one meetings on August 11-12, 2025. Additionally, management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 2:30 PM ET in Boston, MA. The Canaccord presentation will be available via webcast with a 30-day replay option.
Lucid Diagnostics (Nasdaq: LUCD), un'azienda nel settore della diagnostica medica per la prevenzione del cancro in fase commerciale e controllata da PAVmed (Nasdaq: PAVM), ha annunciato la sua partecipazione a due prossime conferenze per investitori previste per agosto 2025.
L'azienda parteciperà al 10° Annuale Needham Virtual MedTech & Diagnostics 1x1 Conference per incontri individuali l'11 e 12 agosto 2025. Inoltre, il management prenderà parte a una tavola rotonda informale durante il Canaccord Genuity 45° Annual Growth Conference il 13 agosto 2025 alle 14:30 ET a Boston, MA. La presentazione di Canaccord sarà disponibile in webcast con la possibilità di rivederla per 30 giorni.
Lucid Diagnostics (Nasdaq: LUCD), una empresa de diagnóstico médico para la prevención del cáncer en etapa comercial y filial de PAVmed (Nasdaq: PAVM), ha anunciado su participación en dos próximas conferencias para inversores en agosto de 2025.
La compañía asistirá a la 10ª Conferencia Anual Virtual Needham MedTech & Diagnostics 1x1 para reuniones individuales los días 11 y 12 de agosto de 2025. Además, la dirección participará en una charla informal en la 45ª Conferencia Anual de Crecimiento Canaccord Genuity el 13 de agosto de 2025 a las 2:30 PM ET en Boston, MA. La presentación de Canaccord estará disponible vía webcast con opción de repetición por 30 días.
Lucid Diagnostics (나스닥: LUCD)는 상업 단계의 암 예방 의료 진단 회사이자 PAVmed (나스닥: PAVM)의 자회사로, 2025년 8월에 열리는 두 개의 투자자 컨퍼런스에 참여할 것임을 발표했습니다.
회사는 2025년 8월 11일부터 12일까지 1대1 미팅을 위한 제10회 연례 니드햄 가상 메드테크 및 진단 1x1 컨퍼런스에 참석할 예정입니다. 또한 경영진은 2025년 8월 13일 오후 2시 30분(동부 시간) 보스턴, 매사추세츠에서 열리는 캐나코어 진위티 제45회 연례 성장 컨퍼런스에서 파이어사이드 채팅에 참여할 예정입니다. 캐나코어 발표는 30일간 재생 가능한 웹캐스트를 통해 제공됩니다.
Lucid Diagnostics (Nasdaq : LUCD), une société de diagnostic médical en prévention du cancer en phase commerciale et filiale de PAVmed (Nasdaq : PAVM), a annoncé sa participation à deux prochaines conférences pour investisseurs en août 2025.
L'entreprise assistera à la 10e conférence annuelle virtuelle Needham MedTech & Diagnostics 1x1 pour des réunions individuelles les 11 et 12 août 2025. De plus, la direction participera à une discussion informelle lors de la 45e conférence annuelle de croissance Canaccord Genuity le 13 août 2025 à 14h30 ET à Boston, MA. La présentation Canaccord sera accessible en webdiffusion avec une option de replay de 30 jours.
Lucid Diagnostics (Nasdaq: LUCD), ein Unternehmen im Bereich der medizinischen Krebspräventionsdiagnostik im kommerziellen Stadium und Tochtergesellschaft von PAVmed (Nasdaq: PAVM), hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im August 2025 angekündigt.
Das Unternehmen wird an der 10. jährlichen Needham Virtual MedTech & Diagnostics 1x1 Conference für Einzelgespräche am 11. und 12. August 2025 teilnehmen. Außerdem wird das Management am 13. August 2025 um 14:30 Uhr ET in Boston, MA, an einem Fireside-Chat während der 45. jährlichen Canaccord Genuity Growth Conference teilnehmen. Die Canaccord-Präsentation wird per Webcast mit einer 30-tägigen Wiedergabeoption verfügbar sein.
- None.
- None.
- 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
- 1x1 Meetings: August 11-12, 2025
- Location: Virtual
- Canaccord Genuity 45th Annual Growth Conference
- Fireside Chat: August 13, 2025, at 2:30 PM ET
- Location:
Boston, MA
The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-302521811.html
SOURCE Lucid Diagnostics
FAQ
When is Lucid Diagnostics (LUCD) presenting at the Canaccord Genuity Conference?
How can investors access Lucid Diagnostics' (LUCD) Canaccord Conference presentation?
Which investor conferences is Lucid Diagnostics (LUCD) attending in August 2025?
What type of company is Lucid Diagnostics (LUCD)?
